SARS-CoV-2 genomic variant surveillance in human and non-human primate populations in Peru

秘鲁人类和非人类灵长类动物种群中的 SARS-CoV-2 基因组变异监测

基本信息

批准号：
10426887
负责人：
Christopher M Barker
金额：
$ 15万
依托单位：
UNIVERSITY OF CALIFORNIA AT DAVIS
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-11 至 2022-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10426887
关键词：
2019-nCoV Address Administrative Supplement Amino Acids Animals Award Breeding COVID-19 pandemic Caring Cities Clinical Communities Dental Detection Diagnosis Disease Outbreaks Emerging Communicable Diseases Ensure Epidemiology Factor Analysis Future Genome Genomics Goals Health Health care facility Human Individual Intelligence Investigation Knowledge Libraries Medical Mutation Nomenclature Oral Outcome Parents Patients Peru Peruvian Population Preparation Primates Protocols documentation Recording of previous events Research Risk Factors Rural SARS-CoV-2 antibody SARS-CoV-2 infection SARS-CoV-2 positive SARS-CoV-2 variant Sampling Seroprevalences Severity of illness Surveillance Program Swab Syndrome Testing Travel Variant Virus Work bioinformatics pipeline cohort data sharing demographics experience genetic variant human disease improved instrument mortality nasopharyngeal swab nonhuman primate novel open data pandemic disease programs repository response syndromic surveillance transmission process

项目摘要

ABSTRACT Characterization of SARS-CoV-2 variants in Peru, which has one of the highest mortality rates in the world, has been limited and represents a significant knowledge gap that can be addressed through increased genomic surveillance activities. Located within the Amazon Basin, Iquitos was one of the first cities in Peru to experience the impact of the COVID-19 pandemic with devasting levels of transmission in March 2020, followed by one of the highest documented seroprevalence rates of anti- SARS-CoV-2 antibodies worldwide, only to have a second wave of transmission from January through March 2021. Utilizing human samples collected in and near Iquitos, the EpiCenter for Emerging Infectious Disease Intelligence (EEIDI) will sequence SARS-CoV-2 isolates and characterize variants from Peru and investigate their association with human disease severity and syndromes, reinfection, travel history, health outcomes, and patient demographics. We will also characterize isolates of SARS-CoV-2 variants from sampled animals, in particular non-human primate populations that closely interact with humans to investigate potential for spillback into future animal reservoirs. This work will ensure rapid and adaptive surveillance of existing and emerging variants, while improving an understanding of which variants are most likely to be involved in future outbreaks.

抽象的秘鲁的SARS-COV-2变体的表征，该变体的死亡率最高之一世界受到限制，代表了一个很大的知识差距，可以通过增加基因组监测活动。 Iquitos位于亚马逊盆地内，是秘鲁的第一个城市经历了199年大流行的影响，而毁灭性水平 2020年3月的传播，其次是抗 - SARS-COV-2抗体在全球范围直到2021年3月。利用在伊基托斯和附近收集的人类样本，新兴的传染病智力（EEIDI）将序列SARS-COV-2分离株和表征秘鲁的变体，并调查其与人类疾病严重程度的关联和综合征，再感染，旅行史，健康结果和患者人口统计。我们也会表征来自采样动物的SARS-COV-2变体的分离株，特别是非人类灵长类动物与人类紧密相互作用以调查溢出潜力到未来动物的潜力水库。这项工作将确保对现有和新兴变体的快速和适应性监视，同时，提高了对哪些变体最有可能参与未来爆发的理解。